Marvel Biosciences Corp. announced an amendment to its non-brokered private placement of unsecured convertible debentures, lowering the conversion price to $0.17 per common share. The offering aims to raise up to $500,000 and remains subject to TSX Venture Exchange approval. Marvel is a pre-clinical biotech company developing MB-204, a drug candidate targeting neurological diseases like Parkinson's, autism, and Alzheimer's. This funding move supports Marvel's ongoing development and research efforts in neurodevelopmental disorders.
The FTSE 100 index fell slightly, dragged down by mining stocks reacting to China's slower GDP growth of 4.3% in Q2, its weakest in three years. Despite this, oil prices remained steady amid US-Iran tensions. PayPal shares jumped over 14% following r...
The Goldman Sachs Future Tech Leaders Equity ETF (GTEK) has delivered a 48.9% return year-to-date, nearly doubling the 25% return of the Vanguard Information Technology ETF (VGT). Unlike VGT, which heavily invests in mega-cap tech giants like Nvidia,...
